Relay Therapeutics competitors

Dr. Johnson Y.N. Lau is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history ($300 million). During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. He played a key role in raising $525 million in convertible bonds that facilitated the restructuring of ICN and the partial spin-off of Ribapharm. Dr. Lau has established an excellent working relationship with a number of prominent investment banks and has extensive experience in establishing strategic partnerships and in negotiating licensing deals including key agreements with Hoffman-La Roche, Anadys, Schering-Plough and Metabasis. Dr. Lau served as the Senior Director of Antiviral Therapy at Schering-Plough from 1997-2000 where he played a significant role in the FDA approval of Ribavirin/Interferon and Pegylated interferon alpha-2b. Dr. Lau has more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and is also a Director of the Board of Chelsea Therapeutics (CHTP) and other privately held companies.

Donald McCaffrey is Chairman of the Board for Zenith Epigenetics Corp. He has held the same positions at Resverlogix Corp. since 2001. Don has 34 years of experience in business management, capital markets and drug discovery & development and in the process has raised over $200 million in drug development capital. Don’s expertise in corporate operations has attracted an international team of R&D experts to Zenith. Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Mount Royal University, Alberta Children's Hospital, Education Matters, and Calgary Urban Project Society Literacy Program. In 2008, Don attended the prestigious World Economic Forum (WEF) in Davos Switzerland as the CEO recipient of a Pioneer Technology of the Year Award Winner and returned to the WEF 2009 event as an invited guest speaker.

Robert Ross is a Board Member at Obsidian Therapeutics, Board Member at SURFACE ONCOLOGY INC., and Chief Executive Officer at SURFACE ONCOLOGY INC. and is based in Brookline, Massachusetts. He has worked as Chief Medical Officer at SURFACE ONCOLOGY INC.. Robert studied at Columbia University in the City of New York between 1995 and 1999, Teachers College Columbia University, and Harvard University between 2005 and 2007.